ArticleOncotarget2017

Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate.

Jessica L Rausch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.